GILEAD SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.86 USD | +0.90% |
|
-1.53% | -18.85% |
| 04:49pm | TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 | MT |
| 04:23pm | Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 | MT |
Financials (USD)
| Sales 2024 * | 27.54B | Sales 2025 * | 27.98B | Capitalization | 81.39B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.93B | Net income 2025 * | 6.76B | EV / Sales 2024 * | 3.57 x |
| Net Debt 2024 * | 16.88B | Net Debt 2025 * | 9.29B | EV / Sales 2025 * | 3.24 x |
| P/E ratio 2024 * |
27.2
x | P/E ratio 2025 * |
12
x | Employees | 18,000 |
| Yield 2024 * |
4.78% | Yield 2025 * |
4.99% | Free-Float | 99.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
More news
| 1 day | +0.41% | ||
| 1 week | -1.92% | ||
| Current month | -10.61% | ||
| 1 month | -9.57% | ||
| 3 months | -17.66% | ||
| 6 months | -16.59% | ||
| Current year | -19.17% |
1 week
64.63
67.90
1 month
64.6373.87
Current year
64.6387.87
1 year
64.6387.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 58 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 215 M€ | +10.97% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 65.75 | +0.74% | 5 633 897 |
| 24-04-25 | 65.27 | -2.70% | 15,171,959 |
| 24-04-24 | 67.08 | +0.07% | 8,467,060 |
| 24-04-23 | 67.03 | +0.12% | 5,240,249 |
| 24-04-22 | 66.95 | +0.28% | 5,622,367 |
Delayed Quote Nasdaq, April 26, 2024 at 11:15 am EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.27
USD
Average target price
84.22
USD
Spread / Average Target
+29.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.17% | 81.39B | |
| +25.96% | 653B | |
| +27.00% | 556B | |
| -6.48% | 354B | |
| +20.25% | 331B | |
| +3.87% | 296B | |
| +12.96% | 233B | |
| +5.57% | 201B | |
| -9.61% | 193B | |
| -6.38% | 144B |
- Stock Market
- Equities
- GILD Stock
